Cite
HARVARD Citation
Wagner, A. et al. (2016). Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. European journal of cancer. pp. 94-101. [Online].